Investment Focus
We invest in companies where we can make the greatest impact. Typically, that means we invest in seed and early-stage biotech companies, based primarily in North America and Europe, who are working on novel therapeutics, platform technologies, diagnostics, or vaccines.
Platform Technologies
Regenerative medicine
Synthetic biology
Microbiome
Gene therapy
Nucleic acid medicine
Novel Theraputics
Neurodegeneration
Immunology
Inflammation
Rare disease
Diagnostics
Neurodegenerative Disorders
Meet our team
Our team of PhDs has rich experience in both business and science, and works closely with our biotech entrepreneurs to bring their innovative products to market faster.
Jeffrey Moore
President
Dr. Jeff Moore joined MPH in 2008 with notable professional experience as a scientist, businessman, and investor. Dr. Moore specializes in biochemistry, infectious disease and immunology, and works closely with our early stage portfolio companies.
Current Companies: F-star, Forge, QurAlis
Education
BSc in Biology
University of New Brunswick/University College London
DPhil in Pathology
University of Oxford
Postdoc in Biochemistry and Molecular Biology
Harvard Medical School
MBA
Massachusetts Institute of Technology
Class 10
Kauffman Fellow
Professional Experience
Research Corporation Technologies, Millennium Pharmaceuticals, Scriptgen
Shota Ozawa
Director
Dr. Shota Ozawa joined MPH in 2023 with a diverse background in business development, alliance management, research collaboration, research in molecular biology, oncology, neurology and nephrology. He leverages his extensive pharmaceutical development experience to help support our portfolio companies.
Education
Master of Science: Biophysics and Biochemistry
Tokyo University
PhD in Medicine
Kyoto University
Professional Experience
Mitsubishi Tanabe Pharma Corporation